KalVista Pharmaceuticals creating a new generation of small molecule protease inhibitors for HAE and DME Hereditary Angioedema (HAE)Diabetic Macular Edema (DME)
News KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference Feb 18, 2021 KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Feb 16, 2021 KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock Feb 10, 2021 All News
KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Feb 16, 2021
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock Feb 10, 2021